» Articles » PMID: 30991618

Effect of Age, Ethnicity, Sex, Cognitive Status and APOE Genotype on Amyloid Load and the Threshold for Amyloid Positivity

Overview
Journal Neuroimage Clin
Publisher Elsevier
Specialties Neurology
Radiology
Date 2019 Apr 18
PMID 30991618
Citations 29
Authors
Affiliations
Soon will be listed here.
Abstract

The threshold for amyloid positivity by visual assessment on PET has been validated by comparison to amyloid load measured histopathologically and biochemically at post mortem. As such, it is now feasible to use qualitative visual assessment of amyloid positivity as an in-vivo gold standard to determine those factors which can modify the quantitative threshold for amyloid positivity. We calculated quantitative amyloid load, measured as Standardized Uptake Value Ratios (SUVRs) using [18-F]florbetaben PET scans, for 159 Hispanic and non-Hispanic participants, who had been classified clinically as Cognitively Normal (CN), Mild Cognitive Impairment (MCI) or Dementia (DEM). PET scans were visually rated as amyloid positive (A+) or negative (A-), and these judgments were used as the gold standard with which to determine (using ROC analyses) the SUVR threshold for amyloid positivity considering factors such as age, ethnicity (Hispanic versus non-Hispanic), gender, cognitive status, and apolipoprotein E ε4 carrier status. Visually rated scans were A+ for 11% of CN, 39.0% of MCI and 70% of DEM participants. The optimal SUVR threshold for A+ among all participants was 1.42 (sensitivity = 94%; specificity = 92.5%), but this quantitative threshold was higher among E4 carriers (SUVR = 1.52) than non-carriers (SUVR = 1.31). While mean SUVRs did not differ between Hispanic and non-Hispanic participants;, a statistically significant interaction term indicated that the effect of E4 carrier status on amyloid load was greater among non-Hispanics than Hispanics. Visual assessment, as the gold standard for A+, facilitates determination of the effects of various factors on quantitative thresholds for amyloid positivity. A continuous relationship was found between amyloid load and global cognitive scores, suggesting that any calculated threshold for the whole group, or a subgroup, is artefactual and that the lowest calculated threshold may be optimal for the purposes of early diagnosis and intervention.

Citing Articles

Retinal vascular changes are associated with PET-based biomarkers of Alzheimer's disease: A pilot study.

Leung K, Chan V, Lam B, Mok V, Cheung C J Alzheimers Dis Rep. 2025; 8(1):1639-1648.

PMID: 40034363 PMC: 11863728. DOI: 10.1177/25424823241300416.


Neuroimaging and biofluid biomarkers across race and ethnicity in older adults across the spectrum of cognition.

Wang W, Asken B, DeSimone J, Levy S, Barker W, Fiala J Ageing Res Rev. 2024; 101:102507.

PMID: 39306249 PMC: 11531386. DOI: 10.1016/j.arr.2024.102507.


Functional measures and AD biomarkers among Hispanic and White non-Hispanic older adults.

Rodriguez M, Mendoza L, Garcia P, Duarte A, Padron D, Marsiske M Alzheimers Dement (Amst). 2024; 16(3):e12632.

PMID: 39130803 PMC: 11316142. DOI: 10.1002/dad2.12632.


Clinical utility of plasma Aβ42/40 ratio by LC-MS/MS in Alzheimer's disease assessment.

Weber D, Taylor S, Lagier R, Kim J, Goldman S, Clarke N Front Neurol. 2024; 15:1364658.

PMID: 38595851 PMC: 11003272. DOI: 10.3389/fneur.2024.1364658.


Diffusion MRI relates to plasma Aβ42/40 in PET negative participants without dementia.

DeSimone J, Wang W, Loewenstein D, Duara R, Smith G, McFarland K Alzheimers Dement. 2024; 20(4):2830-2842.

PMID: 38441274 PMC: 11032550. DOI: 10.1002/alz.13693.


References
1.
Rowe C, Ackerman U, Browne W, Mulligan R, Pike K, OKeefe G . Imaging of amyloid beta in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism. Lancet Neurol. 2008; 7(2):129-35. DOI: 10.1016/S1474-4422(08)70001-2. View

2.
Tang M, Stern Y, Marder K, Bell K, Gurland B, Lantigua R . The APOE-epsilon4 allele and the risk of Alzheimer disease among African Americans, whites, and Hispanics. JAMA. 1998; 279(10):751-5. DOI: 10.1001/jama.279.10.751. View

3.
Murrell J, Price B, Lane K, Baiyewu O, Gureje O, Ogunniyi A . Association of apolipoprotein E genotype and Alzheimer disease in African Americans. Arch Neurol. 2006; 63(3):431-4. PMC: 3203415. DOI: 10.1001/archneur.63.3.431. View

4.
Chetelat G, Villemagne V, Bourgeat P, Pike K, Jones G, Ames D . Relationship between atrophy and beta-amyloid deposition in Alzheimer disease. Ann Neurol. 2010; 67(3):317-24. DOI: 10.1002/ana.21955. View

5.
Liu C, Liu C, Kanekiyo T, Xu H, Bu G . Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nat Rev Neurol. 2013; 9(2):106-18. PMC: 3726719. DOI: 10.1038/nrneurol.2012.263. View